General Information of Drug Therapeutic Target (DTT) (ID: TTJ584C)

DTT Name Peroxisome proliferator-activated receptor alpha (PPARA)
Synonyms Peroxisome proliferater-activated receptor alpha; PPARalpha; PPAR-alpha; PPAR; Nuclear receptor subfamily 1 group C member 1; NR1C1
Gene Name PPARA
DTT Type
Successful target
[1]
BioChemical Class
Nuclear hormone receptor
UniProt ID
PPARA_HUMAN
TTD ID
T86591
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFGFTEYQYLGSC
PGSDGSVITDTLSPASSPSSVTYPVVPGSVDESPSGALNIECRICGDKASGYHYGVHACE
GCKGFFRRTIRLKLVYDKCDRSCKIQKKNRNKCQYCRFHKCLSVGMSHNAIRFGRMPRSE
KAKLKAEILTCEHDIEDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPPFV
IHDMETLCMAEKTLVAKLVANGIQNKEAEVRIFHCCQCTSVETVTELTEFAKAIPGFANL
DLNDQVTLLKYGVYEAIFAMLSSVMNKDGMLVAYGNGFITREFLKSLRKPFCDIMEPKFD
FAMKFNALELDDSDISLFVAAIICCGDRPGLLNVGHIEKMQEGIVHVLRLHLQSNHPDDI
FLFPKLLQKMADLRQLVTEHAQLVQIIKKTESDAALHPLLQEIYRDMY
Function
Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2. Ligand-activated transcription factor.
KEGG Pathway
PPAR signaling pathway (hsa03320 )
cAMP signaling pathway (hsa04024 )
Adipocytokine signaling pathway (hsa04920 )
Glucagon signaling pathway (hsa04922 )
Non-alcoholic fatty liver disease (NAFLD) (hsa04932 )
Hepatitis C (hsa05160 )
Reactome Pathway
BMAL1 (R-HSA-1368108 )
PPARA activates gene expression (R-HSA-1989781 )
YAP1- and WWTR1 (TAZ)-stimulated gene expression (R-HSA-2032785 )
Transcriptional activation of mitochondrial biogenesis (R-HSA-2151201 )
Activation of gene expression by SREBF (SREBP) (R-HSA-2426168 )
Transcriptional regulation of white adipocyte differentiation (R-HSA-381340 )
Nuclear Receptor transcription pathway (R-HSA-383280 )
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) (R-HSA-400206 )
Circadian Clock (R-HSA-400253 )
RORA activates gene expression (R-HSA-1368082 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
5 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bezafibrate DMZDCS0 Hypercholesterolaemia 5C80.0 Approved [2]
Ciprofibrate DMGC5DB Hyperlipoproteinemia 5C80 Approved [1]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [1]
Lobeglitazone DMHY3IP Type-2 diabetes 5A11 Approved [3]
Pemafibrate DMD1VZL Hyperlipidemia 5C80.Z Approved [4]
------------------------------------------------------------------------------------
17 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
CS-038 DM67P0F Type-2 diabetes 5A11 Phase 3 [5]
GFT-505 DM7ZOAE Non-alcoholic steatohepatitis DB92.1 Phase 3 [6]
Imiglitazar DM7BCWT Type-2 diabetes 5A11 Phase 3 [7]
MURAGLITAZAR DMG3NFZ N. A. N. A. Phase 3 [8]
Ragaglitazar DMFSHEM Type-1 diabetes 5A10 Phase 3 [9]
TESAGLITAZAR DMGRBN5 Type-1 diabetes 5A10 Phase 3 [10]
ZYH-1 DMMBJYC Lipid metabolism disorder 5C52.Z Phase 3 [11]
GFT14 DMD3RU8 Hyperlipidaemia 5C80 Phase 2 [12]
LY-518674 DMBM2I9 Diabetic complication 5A2Y Phase 2 [13]
Naveglitazar DMD0E8U Diabetic complication 5A2Y Phase 2 [14]
ONO-5129 DMFX3P1 Diabetic complication 5A2Y Phase 2 [15]
ZYH7 DMG7YI9 Dyslipidemia 5C80-5C81 Phase 2 [16]
AVE0897 DM56VG2 Type-2 diabetes 5A11 Phase 1 [17]
CDT-fenofibrate DMKUXB5 Hyperlipidaemia 5C80 Phase 1 [18]
GW-409544 DMOE5SZ Hyperlipidaemia 5C80 Phase 1 [19]
Oxeglitazar DMN4LMT Gout FA25 Phase 1 [20]
TPST-1120 DMG4U32 Solid tumour/cancer 2A00-2F9Z Phase 1 [21]
------------------------------------------------------------------------------------
⏷ Show the Full List of 17 Clinical Trial Drug(s)
3 Patented Agent(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flavonoid derivative 8 DM4O9T3 N. A. N. A. Patented [22]
PMID25416646-Compound-Figure5-A DM9OHAN N. A. N. A. Patented [22]
PMID25416646-Compound-Figure5-H DMCJTU1 N. A. N. A. Patented [22]
------------------------------------------------------------------------------------
22 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aleglitazar DMTG18I Type-2 diabetes 5A11 Discontinued in Phase 3 [23]
AVE-0847 DMRYK1C Hyperlipidaemia 5C80 Discontinued in Phase 2 [24]
AVE-8134 DMCX6MD Heart failure BD10-BD13 Discontinued in Phase 2 [25]
BM-17.0744 DM7ZI8A Type-1 diabetes 5A10 Discontinued in Phase 2 [26]
GSK-677954 DM5WRJX Non-alcoholic fatty liver disease DB92 Discontinued in Phase 2 [27]
Indeglitazar DMS56UD Type-2 diabetes 5A11 Discontinued in Phase 2 [28]
KRP-101 DMBU9O4 Hyperlipidaemia 5C80 Discontinued in Phase 2 [29]
KRP-297 DM9VHZC Type-2 diabetes 5A11 Discontinued in Phase 2 [30]
NS-220 DMQ82T5 Hyperlipidaemia 5C80 Discontinued in Phase 2 [31]
Reglixane DMIN73Y Diabetic complication 5A2Y Discontinued in Phase 2 [15]
Sodelglitazar DMJ816F Hyperlipidaemia 5C80 Discontinued in Phase 2 [32]
AR-H049020 DMHZN42 Type-1 diabetes 5A10 Discontinued in Phase 1 [33]
DRF 10945 DMOPM7L Hyperlipidaemia 5C80 Discontinued in Phase 1 [34]
E-3030 DMJWR1I Hyperlipidaemia 5C80 Discontinued in Phase 1 [35]
LG-101280 DM0PXGU Arteriosclerosis BD40 Discontinued in Phase 1 [36]
LY-929 DMVYG5X Lipid metabolism disorder 5C52.Z Discontinued in Phase 1 [37]
MP-136 DMK91WR Lipid metabolism disorder 5C52.Z Discontinued in Phase 1 [38]
BVT-142 DMIYPLU Type-2 diabetes 5A11 Terminated [42]
CS-204 DM1E7H3 Metabolic disorder 5C50-5D2Z Terminated [43]
CS-207 DMFJ4VT Cardiovascular disease BA00-BE2Z Terminated [44]
KRP-105 DMVZSAM Lipid metabolism disorder 5C52.Z Terminated [45]
Sipoglitazar DM5SBUJ Diabetic complication 5A2Y Terminated [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 22 Discontinued Drug(s)
4 Preclinical Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
MC-3001 DMLK2D0 Lipid metabolism disorder 5C52.Z Preclinical [39]
MC-3002 DM7UGY9 Metabolic disorder 5C50-5D2Z Preclinical [15]
PIRINIXIC ACID DM82Y75 Pulmonary fibrosis CB03.4 Preclinical [40]
Romazarit DMZOUX4 Rheumatoid arthritis FA20 Preclinical [41]
------------------------------------------------------------------------------------
25 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid DM2REIN Discovery agent N.A. Investigative [46]
(E)-12-Nitrooctadec-12-enoic Acid DMBQTZL Discovery agent N.A. Investigative [46]
(E)-13-Nitrooctadec-12-enoic Acid DMF74GJ Discovery agent N.A. Investigative [46]
(E)-4-(3,5-dimethoxystyryl)phenol DMYXI2V Discovery agent N.A. Investigative [38]
8S-HETE DMT9SAC Discovery agent N.A. Investigative [47]
AD-5061 DM5WV13 Discovery agent N.A. Investigative [7]
BMS-687453 DMYAPG5 Discovery agent N.A. Investigative [48]
CP-775146 DMANV7R Discovery agent N.A. Investigative [49]
DB-900 DMGRUN1 Type-2 diabetes 5A11 Investigative [50]
Deoxy-Bigchap DMYAJCG Discovery agent N.A. Investigative [51]
DRF 2519 DMTFQG3 Discovery agent N.A. Investigative [52]
eicosatetranoic acid DMAKP20 Discovery agent N.A. Investigative [53]
Fibrates DMFNTMY Dyslipidemia 5C80-5C81 Investigative [54]
GSK-9578 DMW9AN1 Discovery agent N.A. Investigative [1]
GW-2331 DMM8V9E Discovery agent N.A. Investigative [55]
GW7647 DM9RD0C Discovery agent N.A. Investigative [56]
L-165461 DMKBSGN Discovery agent N.A. Investigative [57]
L-796449 DMWTGQM Discovery agent N.A. Investigative [57]
LL-6531 DM6RCES Diabetic complication 5A2Y Investigative [38]
LY-465608 DMK64AZ Discovery agent N.A. Investigative [58]
N-oleoylethanolamide DMJQ4L7 Discovery agent N.A. Investigative [59]
pristanic acid DMTJZQK Discovery agent N.A. Investigative [60]
reglitazar DMQ3ER0 Discovery agent N.A. Investigative [61]
TZD18 DMVCHOX Discovery agent N.A. Investigative [62]
ZY H2 DMN9UCI Discovery agent N.A. Investigative [63]
------------------------------------------------------------------------------------
⏷ Show the Full List of 25 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Type 2 diabetes 5A11 Liver tissue 1.74E-01 -0.17 -0.3
Non-alcoholic fatty liver disease DD91.0 Liver tissue 2.89E-01 -0.25 -0.67
Rheumatoid arthritis FA20 Synovial tissue 1.12E-01 0.35 0.96
Coronary artery disease BA80-BA8Z Peripheral blood 1.54E-03 -0.29 -1.6
------------------------------------------------------------------------------------

References

1 Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
2 Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
3 Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
4 Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810.
5 Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
6 Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
7 A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
8 Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
9 Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
10 Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
11 Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
12 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024296)
13 Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):140-6.
14 The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats... Drug Metab Dispos. 2007 Jan;35(1):51-61.
15 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
16 Clinical pipeline report, company report or official report of Zydus Cadila.
17 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
18 Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998 Nov 10;98(19):2088-93.
19 Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546.
20 Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16.
21 Clinical pipeline report, company report or official report of Tempest Therapeutics.
22 PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
23 Clinical pipeline report, company report or official report of Roche (2009).
24 DOI: 10.1038/scibx.2012.669
25 The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. Acta Pharmacol Sin. 2009 Jul;30(7):935-46.
26 Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol. 2002 Sep;283(3):H949-57.
27 Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58.
28 Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7.
29 Identification of a functional peroxisome proliferator-activated receptor (PPAR) response element (PPRE) in the human apolipoprotein A-IV gene. Biochem Pharmacol. 2009 Sep 1;78(5):523-30.
30 KRP-297, MCC-555. Nihon Rinsho. 2001 Nov;59(11):2200-6.
31 Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6471-5.
32 Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7.
33 CN patent application no. 100577175, Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators.
34 Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 2010 September; 6(5): 657-691.
35 Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.J Pharmacol Sci.2008 Sep;108(1):40-8.
36 A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent... Mol Endocrinol. 2005 Jun;19(6):1593-605.
37 CN patent application no. 1882326, Ppar agonists for the treatment of hcv infection.
38 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 593).
39 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021175)
40 O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3185-90.
41 Fibrates as therapy for osteoarthritis and rheumatoid arthritis A systematic review. Ther Adv Musculoskelet Dis. 2013 February; 5(1): 33-44.
42 A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem. 2004 Sep 24;279(39):41124-30.
43 Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res. 2008; 2008: 679137.
44 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026848)
45 Discovery of cyclic amine-substituted benzoic acids as PPARalpha agonists. Bioorg Med Chem Lett. 2012 Jan 1;22(1):334-8.
46 Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
47 Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem. 1995 Oct 13;270(41):23975-83.
48 Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol... J Med Chem. 2010 Apr 8;53(7):2854-64.
49 Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo. Mol Pharmacol. 2009 Feb;75(2):296-306.
50 CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof.
51 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
52 Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. Eur J Pharmacol. 2004 May 3;491(2-3):195-206.
53 PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol Chem. 1997 Jul;378(7):651-5.
54 Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81.
55 PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independe... Br J Pharmacol. 2003 May;139(1):163-71.
56 Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg Med Chem Lett. 2001 May 7;11(9):1225-7.
57 Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
58 Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists. J Med Chem. 2004 May 6;47(10):2422-5.
59 Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology. 2005 Jun;48(8):1147-53.
60 Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor alpha. J Lipid Res. 2000 Nov;41(11):1801-7.
61 Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9.
62 A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8.
63 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.